诺和诺德新版减肥药CagriSema疗效不敌礼来的替尔泊肽，导致诺和诺德股价在本周内累计跌去两成 多。 诺和诺德股价在本周内累计跌去两成多。 当地时间2月25日，诺和诺德宣布与Vivtex合作开发下一代用于肥胖和糖尿病的口服药物。 在过去的2025年，礼来的明星药物替尔泊肽2025年全年销售额365.07亿美元，超过诺和诺德的司美格鲁 肽2025年销售额（361亿美元），登上了全球"药王"宝座。 诺和诺德不仅要应对礼来的竞争，还要面临司美格鲁肽专利到期与仿制药冲击挑战。司美格鲁肽2026年 3月将在中、印、加拿大等多个市场失去独占权，一些司美格鲁肽仿制药上市在即，还有众多药企在布 局GLP-1赛道。 面对司美格鲁肽核心化合物专利到期挑战，诺和诺德采取的应对措施是，一方面推出口服GLP-1减肥 药，即Wegovy片剂，后者去年12月已在美国获批，成为全球首个用于体重管理的口服GLP-1产品；另 外一方面，继续开发新的疗法，包括CagriSema以及与联邦制药合作的GLP-1/GIP/GCG三靶点UBT251 等。 而诺和诺德的CagriSema在84周治疗展现出23%的减重效果，不及礼来替尔泊肽25.5%的减重 ...

付款总额最高达4.95亿美元 根据双方签订的合作协议，辉瑞将获得埃诺格鲁肽在中国大陆的独家商业化权益，同时先为达生物为许 可产品的药品上市许可持有人，负责许可产品的研发、注册、生产及供应。合作框架下，先为达生物将 有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。 作为先为达生物的核心产品，埃诺格鲁肽是一款具有cAMP偏向性的新型长效GLP-1受体激动剂。偏向 型激动剂的核心优势在于可在不触发过度受体内吞的情况下，保留下游治疗效果（包括胰岛素分泌和食 欲抑制），从而在降糖和减重方面极大增强疗效。 2026年1月底，埃诺格鲁肽在国内获批上市，用于成人2型糖尿病患者的血糖控制，成为全球首个获批上 市的cAMP偏向型GLP-1受体激动剂。此外，其成人长期体重管理适应症的上市许可申请已获国家药监 局受理。 值得注意的是，埃诺格鲁肽是先为达生物第一款获批上市的产品，该公司其余管线产品大多仍处于早期 临床阶段，距离商业化落地尚有一段距离。受此影响，叠加创新药研发的高投入特性，先为达生物长期 处于亏损状态。 财务数据显示，2023年、2024年及2025年上半年，先为达生物研发开支分别为 ...

核心产品获批上市不到一个月，先为达生物就火速敲定与辉瑞中国的商业化合作。2月24日，杭州先为达生物科技股份有限公司（以下简称"先为达生物"） 与辉瑞中国宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液达成商业化战略合作协议，付款总额最高可达4.95亿美元。 埃诺格鲁肽是先为达生物首个获批上市的产品，也是其成立以来重要的商业化落子。此前因无产品商业化，先为达生物长期处于持续亏损状态，此次牵手辉 瑞，是其核心产品在诺和诺德、礼来等跨国巨头与信达等本土药企激烈竞争的GLP-1赛道中，借力突围的关键一步。瞄准千亿级体重管理市场，先为达早已 启动资本化与全球化布局，去年9月底，先为达生物向港交所递交招股书，正式冲刺港股IPO。 作为先为达生物的核心产品，埃诺格鲁肽是一款具有cAMP偏向性的新型长效GLP-1受体激动剂。偏向型激动剂的核心优势在于可在不触发过度受体内吞的 情况下，保留下游治疗效果（包括胰岛素分泌和食欲抑制），从而在降糖和减重方面极大增强疗效。 2026年1月底，埃诺格鲁肽在国内获批上市，用于成人2型糖尿病患者的血糖控制，成为全球首个获批上市的cAMP偏向型GLP-1受体激动剂。此外，其成人 长 ...

随着GLP-1类药物进入更广泛的体重与代谢管理场景，适用人群扩大，市场空间随之放大。 然而，市场竞争也异常激烈。诺和诺德、礼来等跨国巨头占据先发优势，信达生物、恒瑞医药 （600276）等国内龙头凭借本土化优势快速追赶。 根据协议，辉瑞中国将获得该产品在中国大陆的独家商业化权益；同时先为达生物为许可产品的药品上 市许可持有人(MAH)，负责许可产品的研发、注册、生产及供应。先为达生物将有权获得辉瑞中国支付 的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。 "此次合作并非简单的产品买断，而是典型的'研发+商业化'分工模式。'首付款+里程碑付款'的分阶段支 付结构，是制药行业成熟且科学的交易设计，其核心在于风险共担、利益绑定。"上海市卫生和健康发 展研究中心主任金春林对《证券日报》记者表示，首付款解决启动资金问题，里程碑条款激励先为达生 物不仅要确保研发成功、注册成功，还要关注产品上市后的市场表现。产品的未来销售表现越好，先为 达生物可获得的里程碑收益就越高。 在GLP-1赛道竞争日趋白热化的当下，埃诺格鲁肽注射液的核心竞争力在于其"偏向型"机制。该产品由 先为达生物自主研发，已于2026年 ...

以上内容基于公开资料整理，不构成投资建议。 来源：经济观察网 机构观点 经济观察网 硕迪生物（GPCR.OQ）近7天（2026年2月9日至13日）股价呈现连续下跌趋势。根据内部 数据库，截至2月13日收盘，股价报70.07美元，单日下跌2.73%；近5日累计跌幅达6.47%，区间振幅为 14.95%，最低触及69.95美元。成交活跃度分化，2月12日成交额放大至6405万美元（换手率1.24%），2 月13日回落至8924万美元（换手率1.77%）。同期生物技术板块上涨1.32%，但个股表现弱于大盘（纳 斯达克指数跌0.22%）。 多家券商指出，长期看好硕迪生物基于专利合作带来的现金流潜力及口服GLP-1管线的稀缺性。但短期 股价受制于市场情绪波动、板块获利了结压力以及低流动性环境放大波动，资金分歧显著。 近期事件 2025年12月30日，硕迪生物与罗氏及基因泰克达成非独家专利许可协议，获得1亿美元预付款，并有权 收取口服GLP-1药物CT-996未来销售额的低个位数百分比特许权使用费。该合作虽提供非稀释性资金支 持，但近期股价与这一利好形成反差，主要受医药板块轮动、技术面回调及市场对GLP-1赛道竞争加剧 ...

Company Overview - Shodex Bio (GPCR.OQ) has entered into a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million upfront payment and future royalties from oral GLP-1 drug sales [1] - The company's Q3 2025 financial report shows zero revenue and a net loss of $65.8 million, indicating ongoing R&D investments are pressuring short-term profitability [4] Stock Performance - As of February 12, 2026, Shodex Bio's stock price fell by 3.24% to $73.52, with a cumulative decline of 12.82% over the last 20 trading days [2] - The stock price peaked at $94.90 in January 2026 due to acquisition rumors but has since experienced a pullback, with a recent volatility of 22.57% and a low of $72.10 [5] Industry Context - Since January 2026, the pharmaceutical and biotechnology sector has seen accelerated thematic rotation, with profit-taking pressures emerging in the innovative drug field [3] - Concerns about intensified competition in the GLP-1 market, particularly regarding potential impacts from generic drugs, have led to increased caution among investors [3] Market Environment - On the same day, the Nasdaq index fell by 1.84%, reflecting a general increase in market risk aversion [6] - Shodex Bio's trading volume was approximately $24.58 million, indicating that low liquidity conditions may amplify stock price volatility [6]

Group 1 - Eli Lilly's GLP-1/GIP drug Tirzepatide (brand name: Mounjaro) has received approval from the National Medical Products Administration of China for use as a monotherapy in adults with type 2 diabetes, based on the SURPASS-CN-MONO study targeting early patients in China, which is expected to expand market potential in the country [1] - Eli Lilly's IL-23 monoclonal antibody, both intravenous and subcutaneous formulations, has been approved for the treatment of Crohn's disease and ulcerative colitis, enhancing its position in the immunology sector [1] Group 2 - In Q4 2025, Eli Lilly reported revenue of $19.29 billion, a 43% year-over-year increase, exceeding market expectations; adjusted earnings per share were $7.54, up 42% [2] - The Tirzepatide product line generated $36.5 billion in revenue for the year, making it the highest-selling drug globally; the company provided an optimistic revenue guidance for 2026, expecting a range of $80 billion to $83 billion, representing approximately a 25% year-over-year growth [2] Group 3 - Following the positive earnings report and product developments, Eli Lilly's stock experienced significant volatility, with a single-day increase of 10.33% on February 4, 2026, closing at $1,107.12; however, the stock closed at $1,015.21 on February 11, 2026, down 0.96%, with a total decline of 8.30% over the past five trading days, indicating a short-term market adjustment after the positive news [3] Group 4 - CICC released a report on February 10, 2026, noting that Tirzepatide has become the "king of drugs" in 2025, and Eli Lilly has a robust pipeline, with the oral GLP-1 drug Orforglipron expected to receive approval in Q2 2026, which could serve as a new growth driver; the report maintains a neutral rating with a target price of $1,107 [4] - Institutional data shows that 78% of market opinions are buy or hold, reflecting confidence in the long-term prospects of the GLP-1 sector [4]

Core Insights - The global pharmaceutical industry is witnessing a significant shift in the rankings of best-selling drugs, with several products surpassing $10 billion in sales for 2025 [1][2]. Group 1: Sales Performance - Novo Nordisk's semaglutide briefly topped the sales chart in Q1 2025 but was ultimately surpassed by Eli Lilly's tirzepatide, with both drugs exceeding $30 billion in sales [1][3]. - Tirzepatide achieved a remarkable year-on-year sales growth of 121%, while semaglutide's growth was only 13% [3]. - The sales figures for semaglutide in the first half of 2025 reached $16.683 billion, maintaining its position as a top-selling drug [3]. Group 2: Competitive Landscape - The GLP-1 drug class is experiencing intense competition, with both tirzepatide and semaglutide being key players [4][5]. - The market is dominated by Novo Nordisk and Eli Lilly, but Chinese pharmaceutical companies are also making significant strides in this area [5][6]. - New GLP-1 drugs are under development, including Novo Nordisk's CagriSema and Eli Lilly's retatrutide, which shows potential for greater weight loss than tirzepatide [5]. Group 3: Oncology and Autoimmune Drugs - The PD-1 inhibitor pembrolizumab (Keytruda) remains a top seller in oncology, with sales reaching $31.68 billion in 2025, despite falling to third place [7]. - Nivolumab (Opdivo) also crossed the $10 billion mark, achieving sales of $10.29 billion [8]. - In the autoimmune disease sector, drugs like dupilumab and risankizumab achieved sales of $17.8 billion and $17.562 billion, respectively [8]. Group 4: Anticoagulants - The anticoagulant apixaban continues to show strong sales growth, with BMS reporting $14.443 billion in sales, a year-on-year increase of 8% [9]. - Pfizer's reported revenue from apixaban reached $8 billion, making it their second-largest selling product [9].

Core Insights - The pharmaceutical industry is witnessing a significant shift in the rankings of top-selling drugs, with several products surpassing $10 billion in sales for 2025 [1][2] - The competition in the GLP-1 drug category is intensifying, with new entrants like semaglutide and tirzepatide rapidly gaining market share [3][4] Group 1: Top-Selling Drugs - Tirzepatide from Eli Lilly has achieved sales of $365.07 billion, making it the top-selling drug of 2025 [2][3] - Semaglutide from Novo Nordisk follows closely with sales of $361 billion, having briefly surpassed Merck's pembrolizumab (Keytruda) in Q1 2025 [1][3] - Pembrolizumab (Keytruda) recorded sales of $316.8 billion, maintaining a strong position despite falling to third place [7][8] Group 2: Market Dynamics - The sales growth of tirzepatide is remarkable, with a year-on-year increase of 121%, while semaglutide's growth is only 13% [3] - The competitive landscape for GLP-1 drugs is evolving, with multiple companies, including domestic Chinese firms, entering the market with biosimilars and new formulations [4][6] - Novo Nordisk and Eli Lilly are both developing next-generation GLP-1 drugs, with Novo Nordisk's CagriSema and Eli Lilly's retatrutide showing promising clinical results [5] Group 3: Other Notable Drugs - Other significant drugs include nivolumab (Opdivo) from Bristol-Myers Squibb, which achieved sales of $102.87 billion, and daratumumab (Darzalex) with sales of $143.51 billion [8][9] - Apixaban (Eliquis), a leading anticoagulant, continues to grow, with Bristol-Myers Squibb reporting sales of $144.43 billion, reflecting an 8% increase [9]

截止 1月23日当周处方量突破2.6万个 ，口服司美格鲁肽片成为诺和诺德在 2026开年彰显其在糖尿病和肥胖症领域主导地位的代表之作。 在刚刚结束的 2026年JPM医疗健康大会上，诺和诺德并未回避竞争日益加剧的国际市场，反而 释放 出一个 强 有力的 信号： GLP-1 赛道 的下半场， 将由 口服制剂 主导 。 诺和诺德的战略方向正转向主动收缩与聚焦。公司计划在 2026年将业务重新集中至糖尿病与肥胖症两大核心领域，从而结束此前相对分散的业务布局。 此外，该公司预测口服减重药未来将占据重要市场份额，超过三分之一的肥胖患者可能倾向于选择此类疗法，而非传统的注射制剂。 此次战略回归的核心，正是全球首款 口服 大分子药物 ——口服司美格鲁肽片。该药于年初刚刚在美国上市，商品名为 Wegovy Pill 。 1月5日 一经上 市，便迅速成为当地肥胖症市场的明星产品， 处方量从首四天的 3,071个跃升至截至1月16日当周的逾18,000个，并于截至1月23日当周进一步达到 26,109个，展现强劲上市势头 。 口服多肽曾被视为制药界的 "圣杯"。这在科学上极难实现，胃肠道是生物进化的杰作，专门用来防御外来蛋白。胃 ...